Please login to the form below

Not currently logged in
Email:
Password:

gouty arthritis

This page shows the latest gouty arthritis news and features for those working in and with pharma, biotech and healthcare.

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales

Ilaris is an interleukin-1 beta inhibitor and has been on sale since 2009, gradually picking up approvals for a range of inflammatory diseases including juvenile-onset rheumatoid arthritis, gouty arthritis

Latest news

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

  • Grunenthal to market MSD’s pain drug Grunenthal to market MSD’s pain drug

    The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Novartis gets FDA green light for new Ilaris indication. Immunotherapeutic wins US approval for severe form of childhood arthritis. ... arthritis. Efforts to get a gouty arthritis indication in the US were knocked back in 2011, however, when the FDA -

  • Novartis' Ilaris cleared for gouty arthritis in EU Novartis' Ilaris cleared for gouty arthritis in EU

    Novartis' Ilaris cleared for gouty arthritis in EU. First biologic drug approved for condition in Europe. ... Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another gain for the

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics